Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07155070 · ClinicalTrials.gov registry record · Phase 4

Efficacy of Kera Sol Tears on Signs and Symptoms of Surgical Temporary Ocular Discomfort Syndrome (STODS) in Subjects Following LASIK

A Phase 4 study of Dry Eye, sponsored by Vance Thompson Vision.

Recruiting
Registry status
Phase 4
Development phase
60
Enrollment target
1
Study location

NCT07155070 is a Phase 4 study of Dry Eye that is actively recruiting participants, run by Vance Thompson Vision. The registered enrollment target is 60 participants, below the 94-participant average among 41 other Dry Eye trials with a reported enrollment target (36% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07155070, a Phase 4 study of Dry Eye, is actively recruiting participants, sponsored by Vance Thompson Vision.

RECRUITING
Registry status
Phase 4
Development phase
60 participants
Enrollment target
1
Study location

Study Summary

Collecting data using Kera Sol tear usage during the initial two-week post-operative period after Laser-Assisted In Situ Keratomileusis (LASIK) has on the signs and symptoms of surgical temporary ocular discomfort syndrome (STODS)

Conditions Studied

Interventions

  • DRUG Kera Sol Eye Drops

Study Locations (1)

South Dakota

  • Vance Thompson Vision Clinic, Prof. LLC - Sioux Falls

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2025-08-01
Est. Completion 2026-02-01
Phase Phase 4

Sponsor

Vance Thompson Vision

14 total trials

What the Registry Record Tells You About NCT07155070

The ClinicalTrials.gov registry entry for NCT07155070 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 94-participant average among 41 other Dry Eye trials with a reported enrollment target (36% lower). The listed sponsor is Vance Thompson Vision, which has 14 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Dry Eye appearing as the primary indexed condition, and to 1 intervention - of which Kera Sol Eye Drops is the first listed.

NCT07155070 reports 1 study location spanning 1 distinct geographic area - top geographies include South Dakota.

Frequently Asked Questions

What is clinical trial NCT07155070 about?

NCT07155070 is a clinical study titled "Efficacy of Kera Sol Tears on Signs and Symptoms of Surgical Temporary Ocular Discomfort Syndrome (STODS) in Subjects Following LASIK". Collecting data using Kera Sol tear usage during the initial two-week post-operative period after Laser-Assisted In Situ Keratomileusis (LASIK) has on the signs and symptoms of surgical temporary ocular discomfort syndrome (STODS)

What is the current status of trial NCT07155070?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2025-08-01. Estimated completion is 2026-02-01.

What conditions does trial NCT07155070 study?

This clinical trial studies the following conditions: Dry Eye.

What interventions are being tested in trial NCT07155070?

The interventions under investigation include: Kera Sol Eye Drops (DRUG).

Who is sponsoring clinical trial NCT07155070?

This trial is sponsored by Vance Thompson Vision, which has 14 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07155070 being conducted?

This trial has 1 study location across South Dakota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Dry Eye

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.